Note: This article is a human-review proposal based solely on the provided video transcript of Dr. Patrick Nemechek’s discussion. It summarizes his comments and interpretations and is not a substitute for individualized medical care.
In this research review, Dr. Patrick Nemechek discusses a paper that examined whether developing COVID is associated with a higher likelihood of later developing small intestine bacterial overgrowth (SIBO). His key takeaway from the paper is that the increased likelihood of SIBO did not show up immediately after COVID—rather, it appeared more clearly after the six-month mark, with a notable increase between months 6 and 12.
Dr. Nemechek also offers a clinical interpretation of why a delay might occur, connecting it to features he has discussed in other videos about “long COVID,” including prolonged inflammatory signaling and effects on the autonomic nervous system that may slow intestinal motility. He also points to medication patterns after COVID—such as motility-slowing drugs and acid suppressants—that may contribute to SIBO risk.
What the paper reported: a delayed increase in SIBO after COVID
Dr. Nemechek describes the paper as involving a large population (with counts in the hundreds of thousands) and comparing people who had COVID with those who did not, tracking who later developed SIBO.
In his walkthrough of the time course:
- At about 1 month after COVID, there were too few cases to calculate an odds ratio (as he describes it).
- At 3 months, the odds ratio was about 1 (suggesting no difference between groups).
- At 6 months, it was still about the same.
- Beyond 6 months up to ~12 months, he notes a “huge jump” in the likelihood of developing SIBO.
As an example, he cites the 30–39-year-old group with an odds ratio of about 2.7. He explains this as being roughly 2.7 times more likely to have SIBO after COVID than without COVID, and he illustrates it with a concrete comparison: for every 10 people who develop SIBO without COVID, about 24 would develop SIBO after having COVID (in his interpretation of that odds ratio example).
Why might SIBO show up later instead of immediately?
Dr. Nemechek’s central question is the same one many clinicians and patients would ask: why does it take that long? He proposes several possibilities, emphasizing that it may be a mixture of factors.
In his framework: long COVID, inflammatory signaling, and autonomic stress
Referencing his other discussions about “long COVID,” Dr. Nemechek explains that in his view about 25% of people after COVID can develop what he calls “COVID leaky gut,” with a prolonged release of inflammatory cytokines. He describes this as contributing to a range of symptoms affecting joints and organs, and he specifically highlights neurologic stress on the autonomic nervous system.
In his clinical interpretation, autonomic nervous system stress can lead to symptoms such as brain fog and blood pressure-related sensations “in the head,” and it can also slow the intestinal tract down. He notes that slow motility is a risk factor for developing SIBO, and he suggests this could help explain the delayed rise seen in the paper’s time window.
Medication patterns after COVID: motility slowing and acid suppression
Dr. Nemechek also points out that, in the paper’s analysis, there was an increase in certain medications being used after COVID. He highlights two categories that may matter for SIBO risk:
- Medications that slow intestinal motility, including chronic opioid use and antidiarrheal/antispasmodic-type medications he names (e.g., loperamide, dicyclomine, diphenoxylate). In his explanation, these can slow motility “just like” autonomic nervous system effects might.
- Proton pump inhibitors, which he describes as “super potent acid suppressants.” He states that these increase the risk of SIBO and notes that this has been shown in other studies.
In Dr. Nemechek’s telling, one possibility is that post-COVID symptoms lead to prescriptions for these medications, and that the medications (or the conditions prompting their use) may contribute to SIBO developing over time. He does not present a single cause, instead concluding it is likely a combination of contributors.
Why addressing SIBO matters in his clinical approach
Dr. Nemechek emphasizes that, regardless of which factor is most responsible for the association observed in the paper, what matters clinically (in his view) is that SIBO needs to be addressed because it can contribute to and prolong a chronic inflammatory state.
What he says he is doing in new adult patients
Based on this paper and his broader long COVID framework, Dr. Nemechek describes how he is approaching new adult patients in his practice:
- He says he is treating “everybody” with glutamine with the aim of stopping what he refers to as “COVID leaky gut.”
- He also says he has been giving everybody at least one 10-day round of rifaximin to address underlying SIBO.
He describes this combination as seeming to be a “pretty potent combo” for helping people “turn around,” in his clinical experience.
Educational medical disclaimer: This content summarizes a video discussion by Dr. Patrick Nemechek and is for education only. It does not establish what will happen in any individual case and does not replace medical advice, diagnosis, or treatment. If you suspect SIBO, have persistent post-COVID symptoms, or are considering changes to medications (including antibiotics, acid suppressants, or supplements), consult a licensed clinician.
